French pharmaceutical group Servier struck one of oncology’s most significant deals of 2026 on March 6, agreeing to acquire Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) in an all-cash transaction valued at approximately $2.5 billion, or $21.50 per share. That price represents a 68% premium over Day One’s closing price on March 5, and an 86% premium over the one-month volume-weighted average price, a signal of how urgently Servier valued the asset at the center of the deal.
That asset is Ojemda (tovorafenib), an oral, brain-penetrant, pan-RAF kinase inhibitor with FDA approval in the U.S. for relapsed or refractory pediatric low-grade glioma (pLGG) harboring RAF alterations, the most common type of childhood brain tumor, and a freshly issued positive CHMP opinion pointing toward imminent EU authorization. The transaction is expected to close in Q2 2026, pending customary conditions including shareholder tender of a majority of shares and U.S. antitrust clearance. Servier plans to fund it entirely from existing cash.
The Asset at the Core: Tovorafenib’s Mechanism and Clinical Profile
Tovorafenib (Ojemda) is a type II pan-RAF kinase inhibitor, mechanistically distinct from the first-generation BRAF inhibitors that preceded it. Rather than binding the active kinase conformation, tovorafenib binds the inactive conformation of RAF, allowing it to inhibit both monomeric and dimeric RAF signaling. This matters clinically: conventional BRAF inhibitors paradoxically activate the MAPK pathway in tumors driven by RAS mutations or non-V600 BRAF alterations, a liability tovorafenib sidesteps by targeting RAF regardless of its activation state.
The drug’s brain penetrance is the other differentiating feature. Pediatric low-grade glioma is predominantly a central nervous system disease, and the blood-brain barrier has historically restricted the effectiveness of kinase inhibitors in this setting. Tovorafenib’s CNS activity was central to its approval and is central to its competitive positioning.
Ojemda received FDA approval in April 2024 for patients aged 6 months and older with relapsed or refractory pLGG bearing RAF alterations. The CHMP positive opinion issued recently points to an EU approval expected in the coming months, where Ipsen currently holds the commercialization rights to the drug. For Servier, absorbing Day One consolidates the global development narrative around tovorafenib even where commercialization remains partnered.
Beyond the approved indication, Day One was already enrolling patients in a Phase 3 trial evaluating tovorafenib as front-line systemic therapy for pLGG requiring treatment, a readout that, if positive, would expand the drug’s addressable population from the relapsed setting into newly diagnosed patients.
The Pipeline Beyond Tovorafenib: ADCs and Solid Tumor Reach
Tovorafenib accounts for the strategic headline, but Day One brings a developing pipeline that adds meaningful optionality to Servier’s oncology portfolio.
Emi-Le (emilatug ledadotin) is a B7-H4-targeting antibody-drug conjugate (ADC) currently in Phase 1 development for adenoid cystic carcinoma, breast, endometrial, and ovarian cancers. B7-H4 (also known as VTCN1) is a checkpoint ligand overexpressed in a subset of solid tumors, particularly gynecological and salivary gland malignancies, and has attracted growing ADC development interest given its restricted normal-tissue expression and tumor-selective overexpression.
DAY3014 is a PTK7-targeting ADC in a Phase 1 trial for locally advanced or metastatic solid tumors. PTK7 is an orphan receptor tyrosine kinase with elevated expression across multiple tumor types including cervical, gastric, and non-small cell lung cancer. Pfizer’s tisotumab vedotin precedent in PTK7 has helped validate the receptor as a legitimate ADC target, making DAY3014 a strategically relevant asset.
Together, these programs give Servier an early-stage ADC franchise that complements tovorafenib’s kinase inhibitor platform, a portfolio architecture consistent with building durable oncology commercial infrastructure rather than relying on a single asset.
Strategic Context: Completing Servier’s Glioma Franchise
The Servier-Day One deal does not exist in isolation, it is the second major glioma-relevant acquisition Servier has executed in five years, and the strategic logic is cumulative. In 2021, Servier acquired Agios Pharmaceuticals for $2 billion, gaining Voranigo (vorasidenib), which received FDA approval in 2024 for Grade 2 IDH-mutant glioma in patients 12 years and older.
Voranigo and Ojemda now occupy adjacent, non-overlapping niches in glioma: Voranigo in IDH-mutant adult/adolescent low-grade glioma, and Ojemda in RAF-altered pediatric low-grade glioma. The combination creates what Servier can credibly describe as a glioma franchise with coverage across molecular subtypes and age groups, a rare positioning in an indication where the treatment landscape had been largely chemotherapy-dependent for decades.
Olivier Laureau, President of Servier, was direct about the intent:
This acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier’s position in rare oncology.
Olivier Laureau/Servier
Jeremy Bender, Ph.D., CEO of Day One Biopharmaceuticals, framed the rationale from the acquired company’s perspective:
Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases. Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma.
Jeremy Bender/Day One Biopharmaceuticals
Competitive Landscape and Market Implications
Pediatric low-grade glioma represents an underserved but increasingly active space in oncology. The MEK inhibitor binimetinib has been studied in pLGG in combination regimens; dabrafenib plus trametinib (Novartis) received FDA approval for BRAF V600-mutant pLGG in 2023. However, tovorafenib’s pan-RAF mechanism addresses a broader range of RAF alterations, including BRAF fusions and non-V600 mutations, that are common in pLGG but not covered by V600-specific inhibitors. This mechanistic breadth, combined with the brain-penetrant profile and once-weekly oral dosing, distinguishes Ojemda in a competitive but not yet crowded space.
For large pharma, the deal sets a pricing benchmark for commercially active pediatric oncology assets with approved rare disease indications and pipeline optionality. At $2.5 billion for a recently approved drug with active Phase 3 expansion trials and an ADC pipeline, the Servier-Day One transaction signals continued investor and acquirer conviction in rare oncology as a durable value creation category.
Forward-Looking Analysis
The next 12–18 months will be catalytic. EU Commission authorization for Ojemda will generate news flow. The front-line pLGG Phase 3 readout, when available, could expand the approved patient population meaningfully, transforming Ojemda from a second-line drug into a potential first-line standard. On the ADC side, Phase 1 dose-escalation and expansion data for Emi-Le and DAY3014 will begin to define the potential of those programs and their fit within Servier’s broader portfolio strategy.
For the pediatric oncology community, the deal reinforces a structural trend: rare, precision-defined pediatric cancers, once largely overlooked by large pharma, are now commanding billion-dollar premiums as the regulatory and commercial infrastructure around them has matured. The willingness to pay a 68–86% premium for an asset with meaningful near-term catalysts suggests Servier is prioritizing strategic position over short-term financial optimization. In an M&A environment where discipline and patience are often cited as virtues, that is a notable commitment.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada